drugset / Trial / NCT03471650
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Phase 2
Active not recruiting
150 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Progenics Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.
Timeline
- Start
- 2018-03-29
- Primary completion
- 2028-03-07
- Completion
- 2028-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-DCFPyL | Diagnostic / imaging agent | 333 mbq | Intravenous |